Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.680
+0.060 (3.70%)
At close: Dec 20, 2024, 4:00 PM
1.640
-0.040 (-2.38%)
After-hours: Dec 20, 2024, 5:27 PM EST
Chemomab Therapeutics Analyst Ratings
Total Analysts
3
Consensus Rating
Strong Buy
Price Target
$7.33
Upside
+336.31%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $13 → $11 | Buy | Reiterates | $13 → $11 | +554.76% | Nov 15, 2024 |
| Maxim Group | Maxim Group | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +138.10% | May 13, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $6 | Hold → Buy | Upgrades | $6 | +257.14% | May 6, 2024 |
| Oppenheimer | Oppenheimer | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Mar 8, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +316.67% | Dec 19, 2023 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +316.67% | Oct 6, 2023 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 7, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $12 → $7 | Buy | Maintains | $12 → $7 | +316.67% | Apr 18, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $30 → $20 | Buy | Maintains | $30 → $20 | +1,090.48% | Mar 10, 2022 |
| Aegis Capital | Aegis Capital | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +1,685.71% | Dec 7, 2021 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $45 | Buy | Initiates | $45 | +2,578.57% | May 26, 2021 |
| Oppenheimer | Oppenheimer | Buy Initiates $42 | Buy | Initiates | $42 | +2,400.00% | May 7, 2021 |